


# Index



Editorials, Letters to the Editor, Case Reports and Short Reports are indicated by (E), (L), (CR) and (SR) after the page numbers, respectively

- Aalderen WMC van 102-7  
 Abe K 138-40 (CR)  
 Abe S 891-7  
 Abisheganaden J 277-82  
 acetic acid, cough response to 58-61  
 ADA<sub>1</sub>/ADAP ratio in pleural TB 816-21  
 aerobic capacity limitation in ankylosing spondylitis 700-8  
 Agostinis L 709-14  
 Agusti AGN 739-43  
 Ahlner J 584-8  
 airway  
   diseases, bronchial brushing safety and cellular assessment 461-6  
   inflammation evaluation in hyper-responsive cross-country skiers and asthmatics 719-25  
   obstruction, bronchodilator response 630-6  
   responsiveness and atopy in asthma, nitric oxide exhalation relationship to 552-6  
   subepithelial tenascin in asthma, albuterol and nedocromil sodium effects on 445-53  
 Akkaya V 119-22  
 albuterol effects on airway subepithelial tenascin in asthma 445-53  
 Almqvist G 491-7  
 Alsbach GPJ 46-51  
 altitude effects on lung function 739-43  
 Altraja A 445-53  
 alveolar macrophages in lung cancer, interleukin-10 production by 666-71  
 amiodarone lung and emphysema, spirometry normalization in 597-600 (CR)  
 Anderson TJ 236-44, 370 (erratum), (erratum end July issue)  
 Andersson B 563-70  
 Andersson T 79-87  
 Ando M 432-4 (SC)  
 androgens in obstructive sleep apnoea, effects of CPAP on 1-7  
 Androustos G 52-7  
 ankylosing spondylitis, aerobic capacity limitation 700-8  
 Antczak A 389-96  
 antibiotic  
   pre-admission effect on blood cultures in community-acquired pneumonia 208-12  
   prophylaxis and *Aspergillus* colonization in cystic fibrosis patients 835-8  
   therapy inhalation in bronchiectasis and chronic bronchial infection by *Ps. aeruginosa* 476-80  
 alpha<sub>1</sub>-antichymotrypsin mutations in patients with COPD 648-54  
 antitrypsin (alpha<sub>1</sub>)  
   deficiency, in Italy 169-72  
   management in COPD 481-90  
 TAQ I polymorphism in patients with COPD 648-54  
 Antó JM 822-6  
 Aotsuka S 95-101  
 arterial oxygenation, nostril widening and 134-5 (SR)  
 Artés M 173-9  
 Arvå E 563-70  
 Arvidsson M 734-8  
 asbestos exposure in environment, malignant mesothelioma and 349-55  
*Aspergillus* colonization in cystic fibrosis patients, prophylactic antibiotic therapy and 835-8  
*Aspergillus terreus*, bronchocentric granulomatosis from 672-4 (CR)  
 asthma  
   acute adult, severity and management compared to BTS guidelines 8-10  
   adolescent 677-84  
   adult, inhaled corticosteroids for 149-60  
   airway inflammation evaluation in hyper-responsive cross-country skiers and 719-25  
   albuterol and nedocromil sodium effects on airway subepithelial tenascin 445-53  
   attacks, treatment by doctors audit 397-401  
   bambuterol vs salmeterol for nocturnal symptoms in 33-8  
   beclomethasone dipropionate safety in CFC-free propellant system in 27-32  
   targeting to lungs with Spacehaler 424-31  
   with non-CFC propellant 244-51  
   beta-agonists 236-43, 370 (erratum), (erratum end July issue)  
   bronchodilator response in airway obstruction 630-6  
   budesonide via Turbuhaler 230-5  
   compliance 763-9  
   corticosteroid-dependent, eosinophilic inflammation in 183-9  
   corticosteroid therapy 141-6 (L), 292-4 (L)  
   cost-effectiveness of fluticasone propionate and budesonide 402-7  
   deaths, co-morbidity and diagnostic inaccuracy 923-7  
   exercise-induced respiratory symptoms 734-8  
   fluticasone propionate vs. budesonide effect on lung function and exacerbations 613-20  
   health beliefs and compliance with inhaled corticosteroids 88-94  
   house moves, air and heating conditions effects in children 919-22  
   in elderly 146 (L)  
   induced sputum vs blood monitoring for nitric oxide metabolites 912-18  
   inflammatory markers in acute exacerbations of 744-51  
   medical costs in Netherlands 779-87  
   mometasone furoate dry powder inhaler for 603-12

# INDEX

- morbidity index related to fright and bother ideas in community 515-19
- nitric oxide exhalation relationship to airway responsiveness and atopy in 5522-6
- nurse practice 584-8
- patient education for self-management 283-9
- pharmaceutically-based severity stratification 788-93
- prevalence in Asians in UK 16-20
- in Finland 798-809
- review 851-5
- salmeterol and need for inhaled corticosteroid in 863-8
- serum leptin in children treated with inhaled budesonide 268-71
- severe chronic, nebulized fluticasone propionate 689-99
- severity marker, methacholine-induced fall in FEC 277-82
- spirometry and tracheal auscultation agreement in bronchial responsiveness in 102-7
- steroid-dependent, salmeterol/fluticasone propionate inhaler for 876-84
- therapy, patient compliance 856-62
- urinary eicosanoids as marker for clinical response to thromboxane A<sub>2</sub> receptor antagonist in 891-7
- vs. COPD mortality in emergency room 822-6
- work-related, in aircraft engine mechanic 69-70 (CR)
- atopy in asthma, nitric oxide exhalation relationship to airway responsiveness and 552-6
- Aubier M 876-84
- Ayres JG 27-32, 69-70 (CR), 726-33
- Azuma A 752-3 (SC)
- Badur S 119-22
- BAL *see* bronchial alveolar lavage
- Balbi B 169-72
- bambuterol vs. salmeterol for nocturnal symptoms in asthma 33-8
- Bando M 507-14
- Banham SW 700-8
- Barbierato SB 262-7
- Bargon J 835-8
- Barnacle H 689-99
- Barnes N 145-6 (L)
- Barnes NC 402-7
- Barry PW 167-8
- Bateman N 759-62
- Baumelou E 65-8 (CR)
- Baumer JH 919-22
- Baykul C 349-55
- Beccaria M 169-72
- beclomethasone dipropionate
  - inhalation 366-9 (L)
  - new preparation 149-60
  - safety in CFC-free propellant system in asthma 27-32
  - targeting to lungs of asthmatics with Spacehaler 424-31
  - with non-CFC propellant in asthma 244-51
- Bednall R 759-62
- Beelen RJH 262-7
- Benetazzo MG 648-54
- Benfield TL 373-8
- Benvenuti A 39-45
- Berger M 88-94
- Berkman N 338-41
- Berkowitz RB 603-12
- Bernstein DI 603-12
- Berrill WT 923-7
- Berrisoul F 252-61
- beta-agonists
  - for asthma 236-43, 370 (erratum), (erratum end July issue)
  - for COPD 227-9
  - induced inhibition of neutrophil chemotaxis, effect on LFA-1 and Mac-1 expression and polymorphonuclear leukocyte antibacterial activity 416-23
- beta<sub>2</sub>-agonists, inhaled long-acting, user characteristics in Southern Europe 709-14
- beta-blockers worsening of obstructive sleep apnoea 290 (L)
- Bialasiewicz P 389-96
- Bisgaard H 144-5 (L)
- Bitsakou C 52-7
- Björneman P 734-8
- Björner L 719-25
- Björnsson E 744-51
- Blaive B 33-8
- Blomqvist P 230-5
- blood gas measurements, capillary, effects of time delay and temperature 794-7
- blood-patch pleurodesis for secondary spontaneous pneumothorax with persistent air leak 432-4 (SC)
- Boe J 467-73
- Boldy DAR 726-33
- Bombieri C 648-54
- Bone D 898-902
- Boniface DR 794-7
- Bonizzato A 869-74
- Boom S van den 643-7
- Borderas L 739-43
- Boulet LP 613-20
- Bousquet J 183-9, 461-6
- Bowie PE 361-5
- brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale 507-14
- Brant LJ 382-8
- Bratel T 1-7, 79-87
- breath alcohol levels following new formulation metered dose inhaler use 167-8
- breathing techniques, active cycle 660-5
- Breitenstein E 810-15
- Breuer R 338-41
- Bromly CL 923-7
- bronchial alveolar lavage (BAL)
  - cell profiles in Wegner's granulomatosis 498-506
  - cytology to detect non-infectious conditions in ITU 571-8
  - vs. induced sputum for evaluation of sarcoidosis and non-granulomatous interstitial lung disease 827-34
  - vs. lymphocyte activation markers in blood and bronchial biopsies and 563-70
- bronchial biopsies vs. lymphocyte activation markers in blood and BAL 563-70

- bronchial brushing safety and cellular assessment in airways diseases 461-6
- bronchial hyperresponsiveness, serum ECP and urinary LTE4 relationships to 589-96
- bronchial infection by *Ps. aeruginosa*, antibiotic therapy inhalation 476-80
- bronchial responsiveness in asthma, spirometry and tracheal auscultation agreement in 102-7
- bronchiectasis, antibiotic therapy inhalation in 476-80
- bronchiolitis, respiratory syncytial virus, high-frequency oscillatory ventilation 435-40 (CR)
- bronchitis, chronic
- ciprofloxacin suspension efficacy vs. co-amoxiclav tablets 252-61
  - cutaneous hypersensitivity in smokers 491-7
  - Finnish National Guidelines for prevention and treatment 1998-2007 297-332
  - infection in acute exacerbations 845-50
  - prevalence in Finland 798-809
  - promoter variation of tumour necrosis factor- $\alpha$  gene as high risk for 752-3 (SC)
- bronchoalveolar lavage *see* bronchial alveolar lavage
- bronchocentric granulomatosis from *Aspergillus terreus* 672-4 (CR)
- bronchodilator response in airway obstruction 630-6
- bronchoscopy
- fibre-optic, role in organ transplants in patients with pulmonary infections 621-9
  - under local anaesthesia and midazolam sedation, codeine phosphate premedication role in 413-15
  - midazolam sedation for amnesia in 361-5
- Brück WM 21-6
- Bruggeman CA 571-8
- Brun P 33-8
- budesonide
- cost-effectiveness in asthma 402-7
  - effect on lung function and asthma exacerbations 613-20
  - following steroid reversibility test in COPD 715-18
  - inhaled, serum leptin in children with asthma 268-71
  - via Turbuhaler for asthma 230-5
- Burge PS 161-6
- Burke CM 236-44, 370 (erratum), (erratum end July issue)
- Byrd Jr RP 379-81
- Califano C 909-11
- Calverly PMA 161-6
- Caminero J 739-43
- Campbell EJ 481-90
- Campbell LM 236-44, 370 (erratum), (erratum end July issue)
- capsaicin, cough response to 58-61
- carbon dioxide
- elimination in carbonic anhydrase deficiency 536-9
  - responsiveness in nocturnal hypoxaemia from COPD 79-87
- carbonic anhydrase deficiency, carbon dioxide elimination in 536-9
- cardiopulmonary exercise testing in ankylosing spondylitis 700-8
- Carlsson L 183-9
- Carlström K 1-7
- Carter R 700-8
- Casan P 739-43
- Castellani C 869-74
- Castellsague J 709-14
- catecholamines in obstructive sleep apnoea, effects of CPAP on 1-7
- Cattaruzi C 709-14
- Caubarrere I 65-8 (CR)
- Causey AL 180-2
- Cazzola M 227-9 (E), 909-11
- Cecins NM 660-5
- Cederlund K 898-902
- Chalmers GW 202-7
- Chambers CV 88-94
- Chambers DC 726-33
- Champel F 33-8
- Chan-Yeung M 39-45
- Chanez P 183-9, 461-6, 763-9
- Chaou W-T 839-41 (CR)
- Chee CBE 277-82
- Chen C-C 277-82
- Chen S-J 839-41 (CR)
- Chervinsky P 603-12
- Chiu I-S 839-41 (CR)
- Choi I-S 912-18
- chronic obstructive pulmonary disease *see* COPD
- ciprofloxacin suspension efficacy vs co-amoxiclav tablets in chronic bronchitis 252-61
- citric acid, cough response to 58-61
- Clark N 856-62
- Cleary R 515-19
- co-amoxiclav tablets efficacy vs. ciprofloxacin suspension in chronic bronchitis 252-61
- Cobben NAM 571-8
- Cochrane GM 763-9
- Cockcroft DW 597-600 (CR)
- codeine phosphate premedication role in bronchoscopy under local anaesthesia and midazolam sedation 413-15
- Cooper CB 71-2 (L)
- Cooray JHL 655-9
- COPD
- alpha-1-antitrypsin deficiency management 481-90
  - TAQ I polymorphism and alpha<sub>1</sub>-antichymotrypsin mutations in patients with 648-54
  - beta-agonists 227-9
  - bronchodilator response in airway obstruction 630-6
  - compliance with long-term oxygen therapy 333-7
  - Finnish National Guidelines for prevention and treatment 1998-2007 297-332
  - inflammatory markers in acute exacerbations of 744-51
  - inhaled  $\beta$ -adrenergic or anticholinergic agent and gas exchange in 222-3 (L)
  - lung-specific health status measure in outpatients 467-73
  - medical costs in Netherlands 779-87
  - nocturnal oxygen desaturation predictors 202-7
  - oropharyngeal Gram-negative bacillary carriage in 540-5
  - oxitropium bromide dose effect on formoterol-induced bronchodilation in 909-11

# INDEX

- oxygen therapy in Netherlands 46-51
- peak inspiratory flow through Turbuhaler 342-4
- review 851-5
- sleep quality, carbon dioxide responsiveness and hypoxaemic patterns in nocturnal hypoxaemia from 79-87
- spirometry and reversibility testing for patient identification on asthma registers 903-8
- steroid reversibility test plus inhaled budesonide in 715-18
- thiobarbituric acid-reactive substances and hydrogen peroxide levels in expired breath, smoking and 389-96
- treadmill exercise duration and dyspnoea recovery time, effect of oxygen breathing and repeated testing 71 (L)
- treatment and exacerbations 173-9
- ventilation outcomes 290-2 (L)
- vs. asthma mortality in emergency room 822-6
- withdrawal of inhaled corticosteroids 161-6
- cor pulmonale, brain natriuretic peptide levels in chronic respiratory failure with 507-14
- corticosteroid
  - inhaled, for adult asthma 149-60
  - in asthma, salmeterol and need for 863-8
  - compliance in asthma 88-94
  - withdrawal in COPD 161-6
  - treatment of asthma 141-6 (L), 292-4 (L)
- Couderc L-J 65-8 (CR)
- cough induced by low pH 58-61
- Cox CA 770-8
- CPAP
  - effects on pituitary reactivity, androgens and catecholamines in obstructive sleep apnoea 1-7
  - humidifier to reduce upper airway dryness 21-6
- Crawford A 454-60
- Crompton GK 342-4
- Croonenborghs L 613-20
- CT scan modalities showing tracheal stenosis 839-41 (CR)
- Cullen AB 770-8
- Cuss FM 603-12
- cutaneous hypersensitivity in chronic bronchitis in smokers 491-7
- cystic fibrosis
  - nitric oxide inhalation effect on pulmonary function in 579-83
  - patients, prophylactic antibiotic therapy and *Aspergillus* colonization in 835-8
- cytokine production by alveolar macrophages, pentoxifylline effect on 52-7
- D'Amato M 909-11
- Dahl R 863-8
- Dahlén I 744-51
- Dauletbaev N 835-8
- Davidson AC 290-1 (L)
- Davidson AC 8-10
- Davies PDO 540-5
- De Brauwier EIGB 571-8
- Dean G 759-62
- Dent RG 794-7
- Dewar MH 342-4
- Di Perna F 909-11
- Diamon JJ 88-94
- Díaz Nuevo G 816-21
- Dichter JR 373-8
- diens, conjugated, levels in pulmonary TB 272-6
- Dirksen A 685-8
- Dluhy RG 145 (L)
- Dodd ME 71 (L)
- Domingo-Salvany A 822-6
- Dominino JC 552-6
- Donnelly R 141-2 (L)
- Douze JMC 46-51
- Drent M 571-8
- Drobnic F 739-43
- Duce F 739-43
- Ducroix JP 208-12
- Duval ELIM 435-40 (CR)
- Dvorin DJ 603-12
- dyspnoea
  - and pulmonary function impairment in exposed workers 39-45
  - recovery time in COPD, effect of oxygen breathing and repeated testing 71-3 (L)
- Ebbehøj N 885-90
- eformoterol via Turbuhaler in asthma 236-43, 370 (erratum), (erratum end July issue)
- Efthimiou J 689-99
- eicosanoids, urinary, as marker for clinical response to thromboxane A<sub>2</sub> receptor antagonist in asthma 891-7
- Eklberg-Jansson A 563-70
- Ekström T 584-8
- Elbek O 349-55
- Elkholy MM 202-7
- Emi M 752-3 (SC)
- emphysema and amiodarone lung, spirometry normalization in 597-600 (CR)
- EOL Group 173-9
- eosinophil
  - cationic protein, serum, and bronchial hyperresponsiveness 589-96
  - percentage in pleural space, idiopathic spontaneous pneumothorax and 262-7
- eosinophilic inflammation in corticosteroid-dependent asthma 183-9
- Epardeau B 65-8 (CR)
- epoprostenol effect in pulmonary hypertension from systemic sclerosis 75-8
- Erikssen J 467-73
- Eschenbruch C 62-4 (CR)
- exercise
  - induced respiratory symptoms 734-8
  - oxygen cost diagram and six-minute walking distance 810-15
- exostoses, multiple hereditary, thoracic complications 217-19 (CR)
- Fabel H 62-70 (CR)
- Farouk A 202-7

- Farrer M 75-8  
 Faurschou P 863-8  
 Feder G 903-8  
 Ferre J 476-80  
 Ferrer A 476-80  
 FEV<sub>1</sub>  
   effect of gestational parity in healthy women 382-8  
   longitudinal decline, von Willebrand factors, chronic  
     respiratory symptoms and 726-33  
 fibroblast IL-11 production, human lung, prostaglandin E<sub>2</sub>  
   role in 637-42  
 Ficker JH 21-6  
 Fields-Ossorio C 379-81  
 Filicori M 869-74  
 fine particle fraction measurement 123-33  
 Finn AF 603-12  
 Fireman E 827-34  
 Fish JE 788-93  
 Fisher KL 589-96 (CR)  
 Fitting JW 810-15  
 fluticasone propionate  
   cost-effectiveness in asthma 402-7  
   effect on lung function and asthma exacerbations 613-20  
   nebulized, in severe chronic asthma 689-99  
   /salmeterol inhaler for steroid-dependent asthma 876-84  
 Folgering H 643-7  
 FORCE research group 236-44, 370 (erratum), (erratum  
   end July issue)  
 forced vital capacity fall as marker in asthma severity 277-  
   82  
 Forcina A 39-45  
 Foresta C 869-74  
 formoterol-induced bronchodilation in COPD, oxitropium  
   bromide dose effect on 909-11  
 Foschino MP 190-5  
 Foster G 903-8  
 Fozard JL 382-8  
 Frachono I 65-8 (CR)  
 Frandsen J 715-18  
 French Bambuterol Study Group 33-8  
 Frølund L 685-8  
 Fujita J 11-15, 113-18  
 Fyffe J 794-7  
  
 G/GM-CSF causing pulmonary toxicity 65-8 (CR)  
 Galli RL 180-2  
 Ganderton D (ed.) 123-33  
 Garcia-Aymerich J 822-6  
 Garcia-Rodriguez LA 709-14  
 Gärtig S 579-83  
 Gemke RJB 435-40 (CR)  
 genetic factors in lung disease (abstracts A1-A17; Sept  
   issue)  
 gentamicin intra-tracheal delivery with partial liquid  
   ventilation 770-8  
 gestational parity, effect on FEV<sub>1</sub> in healthy women 382-8  
 Gilè LS 648-54  
 Giner J 739-43  
 Glerant JCh 208-12  
 Gloeckner K 498-506  
  
 Godard P 33-8, 183-9, 461-6  
 Görel N 119-22  
 Gram-negative bacillary carriage, oropharyngeal, in COPD  
   540-5  
 Grana JR 788-93  
 Grasemann H 579-83  
 Grief J 827-34  
 Griffiths C 903-8  
 Gross GN 603-12  
 Gross WI 498-506  
 Gruppo I.D.A. 169-72  
 Guarraci P 169-72  
 Gude F 108-12  
 Guido P 190-5  
  
 haemodialysis, tuberculin reactivity and peripheral lym-  
   phocyte subsets in 119-22  
 Hahn EG 21-6  
 Haku T 666-71  
 Hallett C 292-4 (L)  
 Hamman-rich syndrome and radiation 136-40 (CR)  
 Hanchak NA 788-93  
 Hancock M 72-3 (L)  
 Hancox M 220-2 (L)  
 Hanibuchi M 666-71  
 Hanley ME 217-19 (CR)  
 Harik-Khan R 382-8  
 Harrison JE 603-12  
 Hart SR 8-10  
 Hartopp R 552-6  
 Hasegawa Y 432-4 (SC)  
 Haworth CS 71 (L)  
 Hayashi R 637-42  
 Hedman J 589-96  
 Heinig JH 613-20  
 Hellmuth D 208-12  
 Hellström G 79-87  
 Hendrick DJ 923-7  
 Henriksen AH 719-25  
 Herjavec I 230-5  
 Hermine O 65-8 (CR)  
 Herulf M 134-5 (SR)  
 Heuck C 268-71  
 Heuvel MM van den 262-7  
 Heymans HSA 102-7  
 HFA 134a for beclomethasone inhalers in asthma 244-51  
 high-frequency oscillatory ventilation for respiratory syn-  
   cytial virus bronchiolitis 435-40 (CR)  
 Hill A 291-2 (L)  
 Hill AT 481-90  
 Hillerdal G 349-55, 898-902  
 Hipp SJ 770-8  
 Hiraga Y A 408-12  
 Hirasawa M A 408-12  
 Hirsch Th 213-16 (SR)  
 HIV infection, *Pneumocystis carinii* pneumonia, steroid  
   effects on surfactant levels 373-8  
 Hooper MM 62-4 (CR)  
 Holland C 75-8  
 Hooper G 424-31

# INDEX

- Hopkinson R 291-2 (L)
- Horne R 763-9
- Hughes CR 919-22
- humidifier to reduce upper airway dryness during CPAP 21-6
- Hunter CJ 345-8
- hydrogen peroxide levels in expired breath in COPD, smoking and 389-96
- Hyland M 515-19
- hypoxaemic patterns in nocturnal hypoxaemia from COPD 79-87
- Igarashi T 891-7
- iloprost effects in pulmonary veno-occlusive disease 62-4 (CR)
- inflammatory markers in acute exacerbations of asthma and COPD 744-51
- inhalers, new formulation metered dose 167-8
- interleukin-10 production by alveolar macrophages in lung cancer 666-71
- interleukin-11 production, human lung fibroblast, prostaglandin E<sub>2</sub> role in 637-42
- interstitial lung disease, non-granulomatous, induced sputum vs. BAL for evaluation 827-34
- Intrator O 338-41
- ipratropium bromide and gas exchange in COPD 222-3 (L)
- Ishil Y 507-14
- Ishimatsu Y 138-40 (CR)
- Ismail MM 655-9
- ISOLDE Study Group 161-6
- Iwashita T 138-40 (CR)
- Jacobs JA 571-8
- Jager JC 779-87
- Jamieson A 342-4
- Jang A-S 912-18
- Janson C 552-6, 744-51
- Janssens JP 810-15
- Jarad NA 161-6
- Jenkins SC 660-5
- Jensen BN 373-8
- Jensen V 885-90
- Jiménez Castro D 816-21
- Johansen JS 885-90
- Johnson A 397-401
- Jolobe OMP 146 (L)
- Jones JI 424-31
- Jones K 515-19, 923-7
- Jones P 856-62
- Jones RCM 919-22
- Jönsson E 798-809
- Joore MA 779-87
- Jørgensen N 734-8
- Jounieaux V 208-12
- Kadota J 138-40 (CR)
- Kamei T 11-15, 113-18
- Kampelmacher MJ 46-51
- Kampmann JP 715-18
- Kaneko S 891-7
- Kanstrup I-L 196-201, 885-90
- Karetzky M 603-12
- Kasielski M 389-96
- Kato H 536-9
- Kauppinen R 283-9
- Kawasaki Y 672-4 (CR)
- Kazi D 52-7
- Keaney NP 75-8
- Kearlsey N 252-61
- Keicho N 752-3 (SC)
- Keller S 856-62
- Kemp J 677-84
- Kemp JP 603-12
- Kempe G 213-16 (SR)
- ketotifen in adolescent asthma 677-84
- Kitagawa C 432-4 (SC)
- Kitamura S 507-14
- Kobayashi K 672-4 (CR)
- Kobayashi M 113-18, 637-42
- Kofoed-Enevoldsen A 885-90
- Köhler B 835-8
- Kohno S 138-40 (CR)
- Kolsuz M 349-55
- Kontozoglou T 52-7
- Koskela K 297-332
- Kotaniemi J 798-809
- Kramer MR 621-9
- Kubin R 252-61
- Kudoh S 752-3 (SC)
- Kumazawa A 432-4 (SC)
- Kuss A 252-61
- Kwiatkowska S 272-6
- La Sala GB 869-74
- lactate dehydrogenase isoenzyme analysis for pleural effusion diagnosis in haemato-oncological patients 338-41
- Laforce C 603-12
- Lagerstrand L 79-87
- Laitinen A 445-53
- Laitinen LA 297-332, 445-53, 798-809
- Lammers J-WJ 46-51
- Lange P 333-7
- Lantero S 416-23
- Larsen F 898-902
- Larsson S 491-7
- Lasch L 88-94
- Läspä SL 798-809
- Lawrence M 373-8
- Leach C 367-9 (L)
- Lee M-L 839-41 (CR)
- Lehnert G 21-6
- Leidl R 779-87
- Leone FT 788-93
- leptin, serum, in asthma treated with inhaled budesonide 268-71
- Lerman Y 827-34
- Leroy PLJM 435-40 (CR)
- leukotriene E<sub>4</sub>, urinary, and bronchial hyperresponsiveness 589-96

- leukotriene modifiers in adolescent asthma 677-84
- LFA-1 expression, beta-agonist-induced inhibition of neutrophil chemotaxis, effect on 416-23
- Lindberg M 584-8
- Little SA 202-7
- Livingstone A 903-8
- Lloyd-Owen SJ 454-60
- Löfdahl C-G 563-70
- Löfroos A-B A 408-12
- Longstaff M 290 (L)
- Lossos IS 338-41
- Lou C 382-8
- Lourens MS 102-7
- Löwhagen O 734-8, 851-5
- Lúdviksdóttir D 552-6
- Luisetti M 169-72, 648-54
- Lumry W 603-12
- Lundbäck B 798-809
- Lundberg JON 134-5 (SR)
- Lundgren JD 373-8
- lung
- cancer
    - interleukin-10 production by alveolar macrophages in 666-71
    - interstitial pneumonia and 754-6 (CR)
    - disposition of inhaled drugs 123-33
    - disease, genetic factors (abstracts A1-A17; Sept issue)
    - function, altitude effects on 739-43
    - thoracentesis effect on 196-201
    - specific health status measure in COPD outpatients 467-73
    - squamous cell carcinoma, pulmonary alveolar proteinosis with 138-40 (CR)
  - lymphocyte
    - activation markers in blood vs. bronchial biopsies and BAL 563-70
    - subsets, peripheral, tuberculin reactivity in haemodialysis and 119-22
- Lynch DA 217-19 (CR)
- Mac-1 expression, beta-agonist-induced inhibition of neutrophil chemotaxis, effect on 416-23
- MacPherson S 788-93
- Madsen F 685-8, 863-8
- Makker HK 69-70 (CR)
- Malerba G 648-54
- Malik MA 546-51
- malondialdehyde levels in pulmonary TB 272-6
- Maltbæk N 715-18
- Mamun M 356-60
- Man A 827-34
- Maraabini A 39-45
- Markson L 88-94
- Markworth S 62-4 (CR)
- Marques-Magallanes JA 71-2 (L)
- Marran S 445-53
- Märston T 445-53
- Martin N 397-401
- Maruyama M 637-42
- Massi G 169-72
- Massobrio M 169-72, 648-54
- Mastella G 869-74
- Matai R 58-61
- Matera MG 227-9 (E), 909-11
- Matsubara Y 138-40 (CR)
- Matsui S 637-42
- Mayordomo C 173-9
- Mazzarella G 909-11
- McDermott P 788-93
- McFarlane D 822-6
- McLean A 342-4
- Melissant CF 46-51
- Menichicchi FM 169-72
- Mendelson LM 603-12
- Meriste S 445-53
- mesothelioma, malignant, asbestos exposure in environment and 349-55
- methacholine-induced fall in FEC as marker of asthma severity 277-82
- Metintas M 349-55
- Metintas S 349-55
- Meyer M 21-6
- midazolam sedation
  - for amnesia in bronchoscopy 361-5
  - for bronchoscopy, codeine phosphate premedication role in 413-15
- Milanowski J 245-51
- Milford Ward A 481-90
- Mino T 637-42
- Miravittles M 173-9
- Miyazaki N 891-7
- Mobbs KJ 540-5
- Mochizuki T 95-101
- Moilanen E 589-96
- Möller M 584-8
- Möllers MJ 613-20
- Mølvig J 885-90
- mometasone furoate dry powder inhaler for asthma 603-12
- Montané F 33-8
- Montellà N 822-6
- Montiel GC 523-35, 630-6
- Morice AH 58-61
- Morrell CH 382-8
- Müller-Quernheim J 498-506
- Murciano D 33-8
- muscle function in ankylosing spondylitis 700-8
- Mutlu S 349-55
- Mycobacterium vaccae* immunotherapy effect on TB 557-62
- Mycobacterium avium-intracellulare* complex, chest CT follow-up 11-15
- Myers P 16-20
- myocardial infarction and snoring 108-12
- Nadeem MA 546-51
- Nakamura Y 113-18, 138-40 (CR), 413-15
- Nakano H 672-4 (CR)
- Nakata K 752-3 (SC)
- nebuliser, ultrasound, sputum induction success with 345-8
- nedocromil sodium effects on airway subepithelial tenascin in asthma 445-53

# INDEX

- Nelson H 603-12  
 Nerin I 739-43  
 Newman SP 366-7 (L), 424-31  
 Nick JA 217-19 (CR)  
 Nicolau F 173-9  
 Nielsen C 715-18  
 Nielsen LP 863-8  
 Nielsen TL 373-8  
 Nieminen MM 589-96  
 Nii M 11-15  
 Nilsson O 563-70  
 nitric oxide  
   effects in pulmonary veno-occlusive disease 62-4 (CR)  
   exhalation relationship to airway responsiveness and atopy in asthma 552-6  
   inhalation effect on pulmonary function in cystic fibrosis 579-83  
   metabolites in asthma, induced sputum vs. blood monitoring 912-18  
   role in nostril widening and arterial oxygenation 134-5 (SR)  
 Nolop KB 603-12  
 Nørgaard M 715-18  
 normality criteria selection 523-35  
 nostril widening and arterial oxygenation 134-5 (SR)  
 Nowak D 272-6, 389-96  
 Nusair S 621-9  
  
 O'Brien J 689-99  
 O'Callaghan C 167-8  
 Obayashi Y 11-15  
 obstructive sleep apnoea  
   beta-blockers worsening of 290 (L)  
   effects of CPAP on pituitary reactivity, androgens and catecholamines 1-7  
   expiratory phase role 190-5  
 Oddera S 416-23  
 Ohishi N 752-3 (SC)  
 Ohmichi M 891-7  
 Ohmichi MA 408-12  
 Ohmoto Y 666-71  
 Ohtsuki Y 113-18  
 Oka M 138-40 (CR)  
 Olsen F 196-201  
 omega-3 and -6 fatty acid consumption in Germany, pre- and post-unification 213-16 (SR)  
 organ transplants, role of fibre-optic bronchoscopy in patients with pulmonary infections 621-9  
 Oriols R 476-80  
 Ormerod LP 16-20  
 oropharyngeal Gram-negative bacillary carriage in COPD 540-5  
 Ostinelli J 33-8  
 Otero Otero Y 108-12  
 Ouchi Y 222-3 (L)  
 oxitropium bromide dose effect on formoterol-induced bronchodilation in COPD 909-11  
 oxygen  
   breathing effect in COPD on treadmill exercise duration and dyspnoea recovery time 71 (L)  
   cost diagram and six-minute walking distance 810-15  
   desaturation predictors, nocturnal, in COPD 202-7  
   therapy for chronic bronchitis and COPD 297-332  
   in COPD in Netherlands 46-51  
   long-term, compliance 333-7  
 Özdemir N 349-55  
  
 Paggiaro PL 39-45  
 Pallarés E 816-21  
 Pallasaho P 798-809  
 panbronchiolitis promoter variation of tumour necrosis factor-alpha gene as high risk for 752-3 (SC)  
 Pangelley J 660-5  
 Parameswaran K 75-8  
 Parashchak MR 236-44, 370 (erratum), (erratum end July issue)  
 Partridge MR 454-60  
 Patel KR 202-7  
 patient  
   compliance in asthma 763-9, 856-62  
   education for self-management in asthma 283-9  
   health beliefs in asthma 88-94  
 Pavord ID 345-8  
 peak inspiratory flow through Turbuhaler in COPD 342-4  
 Pearlman D 603-12  
 Pedersen B 863-8  
 pentoxifylline effect on cytokine production by alveolar macrophages 52-7  
 Pérez G 822-6  
 Pérez Walton IJ 816-21  
 Pérez-Gutthann S 709-14  
 Pérez-Rodríguez E 816-21  
 Perrin VL 245-51  
 Peterson CGB 744-51  
 phosphoric acid, cough response to 58-61  
 Piasecka G 272-6  
 Picca V 190-5  
 Pieters WR 876-84  
 Pietinalho A 408-12  
 Pietras T 389-96  
 Pignatti PF 648-54  
 Pinnock H 397-401  
 Piotrowski W 272-6  
 Pitcairn GR 366-7 (L)  
 pituitary reactivity in obstructive sleep apnoea, effects of CPAP on 1-7  
 pleural effusion diagnosis in haemato-oncological patients, lactate dehydrogenase isoenzyme analysis for 338-41  
 pleural fluid analysis in idiopathic spontaneous pneumothorax 262-7  
 pleural TB, ADA<sub>1</sub>/ADAP ratio in 816-21  
 pleurodesis impact in malignant effusion on respiratory function 898-902  
*Pneumocystis carinii* pneumonia in HIV infection, steroid effects on surfactant levels 373-8  
 pneumonia  
   community-acquired, pre-admission antibiotic effect on blood cultures 208-12  
   interstitial, and primary lung cancer 754-6 (CR)  
   non-specific interstitial, clinical features 113-18

# INDEX

- Sato H 413-15  
 Sato M 432-4 (SC)  
 Satoh T 95-101  
 Scarpelli F 190-5  
 Schattenkerk J 373-8  
 Schayck CP van 643-7  
 Schlösser NJJ 876-84  
 Schmit JL 208-12  
 Schnabel A 498-506  
 Schouten JP 102-7  
 Schulz A 62-4 672-4 (CR)  
 Schwarz MI 217-19 (CR)  
 Schwarz Y 827-34  
 Seale JP 141-2 (L)  
 Segal AT 603-12  
 Segú J-L 173-9  
 Selner JC 603-12  
 Selroos O A 408-12  
 Senderovitz T 715-18  
 Serrano A 230-5  
 Settipane GA 603-12  
 Shaffer TH 770-8  
 Shaw 149-60  
 Shelhamer J 373-8  
 Shima K 432-4 (SC)  
 Shimokata K 432-4 (SC)  
 Shishido S 672-4 (CR)  
 Sillatsu H 445-53  
 Silvestri M 416-23  
 Simmons JL 27-32  
 Singh M 552-6  
 Singh Marlowe G 903-8  
 Sintonen H 283-9  
 Siracusa A 39-45  
 sleep  
   quality in nocturnal hypoxaemia from COPD 79-87  
   -related breathing disorders screening costs in snorers 454-60  
   see also obstructive sleep apnoea  
 Smit HJM 262-7  
 smoking  
   cutaneous hypersensitivity in chronic bronchitis 491-7  
   prevention by dentists 297-332  
   and thiobarbituric acid-reactive substances/hydrogen peroxide levels in expired breath in COPD 389-96  
 Snell NJC (ed.) 123-33  
 snoring  
   and myocardial infarction 108-12  
   respiratory sleep-related breathing disorders screening costs 454-60  
 Sone S 666-71  
 Sovijärvi ARA 798-809  
 Spacehaler, beclomethasone dipropionate targeting to lungs of asthmatics with 424-31  
 spirometry  
   normalization in emphysema and amiodarone lung 597-600 (CR)  
   office 685-8  
   for patient identification with COPD on asthma registers 903-8  
   reference values 523-35  
   and tracheal auscultation agreement in bronchial responsiveness in asthma 102-7  
   volume calibration in 643-7  
 Sprickelman AB 102-7  
 sputum induction  
   success with ultrasonic nebuliser 345-8  
   vs. BAL for evaluation of sarcoidosis and non-granulomatous interstitial lung disease 827-34  
 squamous cell carcinoma, lung, pulmonary alveolar proteinosis with 138-40 (CR)  
 Stableforth D 291-2 (L)  
 Stålenheim G 744-51  
 Stampone P 27-32  
 Stanford C 552-6  
 Stanford J 552-6  
 Star LM van der 643-7  
 Stavem K 467-73  
 Steed KP 424-31  
 Steinmetz K-O 876-84  
 Stelianides S 65-8 (CR)  
 Stern M 65-8 (CR)  
 steroid  
   effects on surfactant levels, *Pneumocystis carinii* pneumonia in HIV infection, 373-8  
   reduction by nebulized fluticasone propionate 689-99  
   reversibility test plus inhaled budesonide in COPD 715-18  
 Stockley RA 481-90  
 Storer TW 71-2 (L)  
 Sturrock RD 700-8  
 Sue-Chu M 719-25  
 Suemitsu I 11-15, 113-18  
 Sugiyama E 637-42  
 Sugiyama Y 507-14  
 Sûkrû Sever M 119-22  
 Summers RL 180-2  
 Sunderland D 540-5  
 Sunyer J 822-6  
 surfactant levels, *Pneumocystis carinii* pneumonia in HIV infection, steroid effects on 373-8  
 Suzuki Y 666-71  
 systemic lupus erythematosus, clinical and laboratory features 95-101  
 systemic sclerosis, epoprostenol effect in pulmonary hypertension from 75-8  
 Szeffler SJ 142-4 (L)  
 Taguchi Y 752-3 (SC)  
 Takahara J 11-15, 113-18  
 Takeuchi E 666-71  
 Taki H 637-42  
 Taki K 536-9  
 Talini D 39-45  
 Tanaka H 891-7  
 Tarodo de la Fuente P 183-9  
 Tassiopoulou A 52-7  
 Taylor IK 75-8  
 tenascin in asthma, airway subepithelial, albuterol and nedocromil sodium effects on 445-53

- pneumothorax  
diagnosis following aspiration of pulmonary lesions 379-81  
idiopathic spontaneous, pleural fluid analysis in 262-7  
secondary spontaneous, blood-patch pleurodesis 432-4 (SC)  
Pohl K 62-70 (CR)  
polymorphonuclear leukocyte antibacterial activity, neutrophil chemotaxis beta-agonist-induced inhibition, effect on 416-23  
Polyzogopoulou C 52-7  
Posselt H-G 835-8  
Postma MJ 779-87  
Postmus PE 262-7  
Poulakis N 52-7  
Poussa T 589-96  
Pradal U 869-74  
Prescott RJ 16-20  
Price J 677-84  
Price MJ 402-7  
prostaglandin E<sub>2</sub> role in human lung fibroblast IL-11 production 637-42  
Provata A 52-7  
*Pseudomonas aeruginosa*, antibiotic therapy inhalation chronic bronchial infection by 476-80  
pulmonary alveolar proteinosis with lung squamous cell carcinoma 138-40 (CR)  
pulmonary damage following zinc chloride smoke exposure 885-90  
pulmonary disease in lupus 95-101  
pulmonary eosinophilia, tropical, diagnostic criteria 655-9  
pulmonary function  
in ankylosing spondylitis 700-8  
in cystic fibrosis, nitric oxide inhalation effect on 579-83  
impairment and dyspnoea in exposed workers 39-45  
tests, understanding amongst trainee doctors 356-60  
pulmonary hypertension from systemic sclerosis, epoprostenol effect in 75-8  
pulmonary infections, role of fibre-optic bronchoscopy in organ transplant 621-9  
pulmonary lesions, pneumothorax diagnosis following aspiration of 379-81  
pulmonary toxicity of chemotherapy and G/GM-CSF 65-8 (CR)  
pulmonary veno-occlusive disease, effects of inhaled nitric oxide and aerosolized iloprost 62-4 (CR)  
Purcell I 75-8  
Quadrelli S 523-35  
Quadrelli SA 630-6  
Qualtrough J 245-51  
Qvarfordt I 491-7  
Rachelefsky G 603-12  
radiation, Hamman-rich syndrome and 136-40 (CR)  
Ramsay G 571-8  
Ratjeb F 579-83  
Ratner P 603-12  
Raza SN 546-51  
Read RC 252-61, 845-50  
rehabilitation for chronic bronchitis and COPD 297-332  
Rephser L 603-12  
respiratory disease, mild, in absence of vas deferens 869-74  
respiratory failure with cor pulmonale, brain natriuretic peptide levels in 507-14  
respiratory function  
assessment 523-35  
pleurodesis impact in malignant effusion on 898-902  
respiratory muscle function in ankylosing spondylitis 700-8  
respiratory sleep-related breathing disorders screening costs 454-60  
respiratory symptoms  
chronic, von Willebrand factors and FEV1 longitudinal decline 726-33  
exercise-induced 734-8  
respiratory syncytial virus bronchiolitis, high-frequency oscillatory ventilation 435-40 (CR)  
Resta B 190-5  
Reuter M 498-506  
reversibility testing for patient identification with COPD on asthma registers 903-8  
Riantawan P 700-8  
Riise GC 491-7  
Ringbaek T 333-7  
Roberts CM 454-60  
Rochat T 810-15  
Rodriguez M 180-2  
Rodriguez-Suárez JR 108-12  
Rogers TK 136-7 (CR)  
Roig J 476-80  
Roland Petersen J 196-201  
Rollof J 491-7  
Romagnoli M 183-9, 461-6  
Roncoroni A 523-35  
Roncoroni AJ 630-6  
Rosell A 476-80  
Rossi GA 416-23  
Roy TM 379-81  
Rubi J 816-21  
Rutten-van Mölken MPMH 779-87  
Ryan G 660-5  
Saarelainen SvLaher M 689-99  
Saene HKF van 540-5  
Saitoh T 891-7  
salmeterol  
/fluticasone propionate inhaler for steroid-dependent asthma 876-84  
and gas exchange in COPD 222-3 (L)  
and need for inhaled corticosteroid in asthma 863-8  
via pressurized metered dose inhaler or Accuhaler in asthma 236-43, 370 (erratum), (erratum end July issue)  
vs. bambuterol for nocturnal symptoms in asthma 33-8  
Sampol G 476-80  
Sánchez Hernández JJ 816-21  
Sánchez-Agudo L 173-9  
Sandek K 79-87  
sarcoidosis  
familial, in Finland and Japan 408-12  
induced sputum vs. BAL for evaluation 827-34

- Teramoto S 222-3 (L), 891-7  
 theophylline in adolescent asthma 677-84  
 thiobarbituric acid-reactive substances levels in expired breath in COPD, smoking and 389-96  
 Thomson NC 202-7  
 thoracentesis effect on lung function and transthoracic electric bioimpedance 196-201  
 thromboxane A<sub>2</sub> receptor antagonist in asthma, urinary eicosanoids as marker for clinical response to 891-7  
 Thwaites RMA 402-7  
 Togores B 739-43  
 Tokunaga K 752-3 (SC)  
 Topilsky I 827-34  
 Topilsky M 827-34  
 Torres A 252-61  
 tracheal auscultation and spirometry agreement in bronchial responsiveness in asthma 102-7  
 tracheal stenosis shown by different CT scans 839-41 (CR)  
 transthoracic electric bioimpedance, thoracentesis effect on 196-201  
 Treacher DF 290-1 (L)  
 treadmill exercise duration and dyspnoea recovery time in COPD, effect of oxygen breathing and repeated testing 71 (L)  
 Troncon MG 709-14  
 tropical pulmonary eosinophilia, diagnostic criteria 655-9  
 Tsukioka T 413-15  
 Tsunozuka Y 413-15  
 tuberculin reactivity and peripheral lymphocyte subsets in haemodialysis 119-22  
 tuberculosis  
   badgers and cattle 72-3 (L)  
   bovine, transmission routes 220-2 (L)  
   effects of immunotherapy with *Mycobacteria vaccae* 557-62  
   evidence-based dosage guidelines 759-62  
   pleural, ADA<sub>1</sub>/ADAP ratio in 816-21  
   pulmonary, conjugated dienes and malondialdehyde levels 272-6  
 Tukiainan H 283-9  
 tumour necrosis factor- $\alpha$  gene, promoter variation 752-3 (SC)  
 Turbitt ML 236-44, 370 (erratum), (erratum end July issue)  
 Turbuhaler, peak inspiratory flow in COPD through 342-4  
 Türk S 119-22  
  
 Uçgun I 349-55  
 Ukale V 898-902  
 Ulrik CS 685-8  
 ultrasonic nebuliser, sputum induction success with 345-8  
 Upchurch FC 424-31  
 urinary eicosanoids as marker for clinical response to thromboxane A<sub>2</sub> receptor antagonist in asthma 891-7  
  
 Vachier I 461-6  
 Valentini E 552-6  
 Vallano A 476-80  
 Van Genugten MLL 779-87  
 Van Kesteren RG 46-51  
 vas deferens absence, congenital, mild respiratory disease in 869-74  
  
 Ven AJAM van der 571-8  
 Venge P 744-51  
 ventilation outcomes in COPD 290-2 (L)  
 ventilatory function in healthy Pakistanis 546-51  
 Vermerie P 856-62  
 Vestbo J 715-18  
 Vieg G 39-45  
 Vignola AM 461-6  
 Vilks V 283-9  
 Viskum K 333-7  
 Vitalograph-R belows spirometer 685-8  
 Vittrup Jensen B 196-201  
 volume calibration in spirometry 643-7  
 von Willebrand factors, chronic respiratory symptoms and FEV<sub>1</sub> longitudinal decline 726-33  
 Vught AJ van 435-40 (CR)  
  
 Wagenaar SjSc 571-8  
 Wagner TOF 835-8  
 Wallaert B 33-8  
 Wanderer A 603-12  
 Wang Y-T 277-82  
 Ward R 345-8  
 Wardlaw AJ 345-8  
 Watanabe A 432-4 (SC)  
 Watanabe Y 413-15  
 Watson SA 236-44, 370 (erratum), (erratum end July issue)  
 Webb AK 71 (L)  
 Wedzicha J 903-8  
 Wedzicha JA 161-6  
 Weel C van 643-7  
 Wegener's granulomatosis, bronchoalveolar lavage cell profiles in 498-506  
 Weitzberg E 134-5 (SR)  
 Wennlund A 1-7  
 Westbroek J 689-99  
 Wharton SP 136-7 (CR)  
 Widström O 898-902  
 Wisseemann HG 579-83  
 Wiest GH 21-6  
 Wilcke JTR 863-8  
 Wildman M 291-2 (L)  
 Williams TJ 361-5  
 Wise RA 382-8  
 Wolf M 835-8  
 Wolfson MR 770-8  
 Wolthers OD 268-71  
 Woltmann G 345-8  
 Wong CH 58-61  
 Woodward L-A 180-2  
 Wright D 919-22  
 Wynne HJ 46-51  
  
 Yamadori I 113-18  
 Yamaji Y 113-18  
 Yamamoto M 432-4 (SC)  
 Yamashita N 637-42  
 Yanagawa H 666-71  
 Yano S 672-4 (CR)  
 Yildiz A 119-22

# INDEX

Yildiz P 119-22  
Yoshida I 536-9  
Yoshinaga M 138-40 (CR)  
Yoshinouchi T 113-18  
Young P 397-401  
Yousef Z 794-7

Zamarrón C 108-12  
Zerahn B 196-201, 885-90  
Zieba M 272-6  
zinc chloride smoke exposure, pulmonary damage 885-90  
Zink-Wohlfart C 62-4 (CR)

